Clinical trial Recruiting at 10 sites Phase 3 Interventional Ages 18 to 75

Early continuous hypertonic saline infusion to improve 6-month neurological outcome after traumatic brain injury

Official title: Efficacy of Early Continuous Infusion of Hypertonic Saline Solution on the Neurological Outcome at 6 Months in Traumatic Brain Injured Patients. A Single-blinded, Multicenter, Randomized, Controlled Clinical Trial With Blinded Evaluation of the Primary Outcome.

Run by Nantes University Hospital · NCT07319208 · Data updated 2026-11-12

This trial will test whether giving a continuous intravenous infusion of hypertonic saline early after traumatic brain injury helps people survive and regain independence in daily life at 6 months.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 75 Years
SexAll
Enrollment760 (estimated)
SponsorNantes University Hospital
Academic / other
Locations23 sites (Angers and 22 other locations)
StatusRecruiting
StartedApril 21, 2026
Main results expectedJune 1, 2028
Study endsJune 1, 2029
Registry record updatedJuly 29, 2026
Trial IDNCT07319208 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are ICU patients with traumatic brain injury and Glasgow Coma Scale ≤ 12 who undergo intracranial pressure monitoring and can be enrolled within 12 hours of monitor placement, with appropriate consent and French national health insurance.

Probably not a fit

Patients unlikely to benefit include those with unsurvivable injury (GCS 3 with persistent nonreactive pupils despite treatment), coma from cardiac arrest, major spinal cord injury, or severe cardiac, renal, or hepatic failure, and pregnant patients who are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 interventional trial enrolls intensive care patients with traumatic brain injury at high risk of intracranial hypertension who have intracranial pressure monitoring. Participants receive an early continuous intravenous infusion of hypertonic saline solution, started within the first 12 hours after ICP monitor placement, and are followed for clinical outcomes. The primary focus is on survival and independence in daily activities at 6 months. The trial is led by Nantes University Hospital and conducted at multiple French university hospitals.

Why it matters

Potential benefit: If successful, this approach could increase survival and improve functional independence at six months for patients with traumatic brain injury and high risk of intracranial hypertension.

How similar studies have gone: Hypertonic saline is widely used to lower intracranial pressure and short-term studies show benefit for ICP control, but strong phase 3 evidence showing improved long-term functional outcomes is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient admitted to intensive care unit
* Traumatic brain injury with Glasgow Coma Scale ≤ 12
* Intracranial pressure (ICP) monitoring based on the attending physician's clinical judgment, in accordance with guidelines or clinical/radiological signs considered at risk of intracranial hypertension
* Inclusion during the first 12 hours after Intracranial pressure monitoring placement
* Informed and signed consent
* National health insurance

Exclusion Criteria:

* Glasgow Coma Scale (score = 3) and persistent abnormal pupillaryreactivity despite urgent therapy
* Associated cervical spinal cord injury
* Imminent death and do-not-resuscitate orders
* Coma secondary to cardiac arrest
* Pregnancy (serum or urine test performed in routine care)
* Severe Cardiac insufficiency
* Severe chronic renal insufficiency
* Severe hepatic insufficiency: patient presenting with oedemato-ascitic decompensation of liver cirrhosis or patient with Child-Pugh class C cirrhosis
* High risk of follow-up difficulties after ICU discharge
* Patients under court protection
* Patient who does not speak French

Where it's running

  • CHU de Brest
    Brest, France
    Recruiting
  • CHU Caen Normandie
    Caen, France
    Recruiting
  • CHU de Clermont- Ferrand
    Clermont-Ferrand, France
    Recruiting
  • Hôpital BEAUJON APHP
    Clichy, France
    Recruiting
  • CHU Henri Mondor APHP
    Créteil, France
    Recruiting
  • CHU de Lille
    Lille, France
    Recruiting
Show 17 more locations
  • CHU de Nantes
    Nantes, France
    Recruiting
  • CHU de Nice
    Nice, France
    Recruiting
  • CHU de Rennes
    Rennes, France
    Recruiting
  • CHU de Toulouse
    Toulouse, France
    Recruiting
  • CHU d'Angers
    Angers, France
    Not yet recruiting
  • CH de Annecy Genevois
    Épagny, France
    Not yet recruiting
  • CHU de Grenoble
    Grenoble, France
    Not yet recruiting
  • Hcl
    Lyon, France
    Not yet recruiting
  • Ap-Hm
    Marseille, France
    Not yet recruiting
  • CHU de Nancy
    Nancy, France
    Not yet recruiting
  • CHU Lariboisière, AP-HP
    Paris, France
    Not yet recruiting
  • GHU Paris Cité
    Paris, France
    Not yet recruiting
  • CHU de Poitiers
    Poitiers, France
    Not yet recruiting
  • CHU de Rouen
    Rouen, France
    Not yet recruiting
  • CHU de St- Etienne
    Saint-Etienne, France
    Not yet recruiting
  • CHU de Strasbourg
    Strasbourg, France
    Not yet recruiting
  • CHRU de Tours
    Tours, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.